Pharmaresearch Bio Co (XKRX:217950) ROCE % : 19.74% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharmaresearch Bio Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 19.74%.

Pharmaresearch Bio Co ROCE % Historical Data

The historical data trend for Pharmaresearch Bio Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co ROCE % Chart

Pharmaresearch Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-4.00

2.97

14.07

20.47

19.74

Pharmaresearch Bio Co Semi-Annual Data
	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
ROCE %	Get a 7-Day Free Trial			-4.00	2.97	14.07	20.47	19.74

Pharmaresearch Bio Co ROCE % Calculation

Pharmaresearch Bio Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	7388.331	/	( ( (58905.474 - 19576.908)	+	(63924.953 - 28398.467) )	/ 2 )
	=	7388.331	/	( (39328.566	+	35526.486)	/ 2 )
	=	7388.331	/	37427.526
	=	19.74 %

Pharmaresearch Bio Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	7388.331	/	( ( (58905.474 - 19576.908)	+	(63924.953 - 28398.467) )	/ 2 )
	=	7388.331	/	( ( 39328.566	+	35526.486 )	/ 2 )
	=	7388.331	/	37427.526
	=	19.74 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

Pharmaresearch Bio Co (XKRX:217950) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharmaresearch Bio Co ROCE % Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaresearch Bio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494

Website

http://www.pr-bio.co.kr

Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co Headlines

No Headlines